



LIBI-Diagnostics is a gene-biomarker start-up for early detection of cancer, powered by the next-generation bio-liquid test.

Pain

1. The main problem with the diagnosis of cancer recurrence concerns the unbearable condition compelled on patients in the way that periodic test results give a zero-sum result.
2. That is, if the periodic test gave a negative result, the patient temporarily feels out of the danger zone and prays that this will be the result in the next test.
3. But if the test is positive - the patient has already entered the danger zone, as cancer recurrence is known to be more aggressive, almost resistant to conventional therapies and significantly reduces the overall chances of survival.
4. Detecting metastasis or protein-expression of metastasis in body (or body fluids) signifies cancer that is diagnosed too late.

Solution

1. Gene expression is the initial stage in the development of cancer, meaning it is a preliminary stage for the formation of metastases.
2. The next-generation AURKA gene-expression technology we offer is a cancer diagnostic test (Although the patient may not yet be defined as a cancer patient) that can be done at a very early stage of the development of cancer, as a screening test or a surveillance test.

Market

1. It is a body fluid test, without the need for tumor tissue.
2. The test is needed for medical follow up of cancer patients who are in remission and allow early detection of recurrence.
3. The test allows anyone to preform cancer screening that can diagnose cancer at the earliest stage.

Product

Developing a non-invasive method to detect and quantify AURKA-gene mRNA over-expression by RNA-FISH (fluorescent in situ hybridization) presented in voided Urine samples.

Co-Founder & CEO

David Risin Attorney

Master of Real Estate
(Technion, Israel Institute of Technology)



Co-Founder & CMO

Dr. Ayelet Ben Barak

Senior physician in
Pediatric Hematology-
Oncology.



Seed Funding

Year 1 - Optimization of methods in normal voided urine samples mixed with rhabdoid tumors cell lines - \$200K (University requirements).

Year 2 - Optimization of methods in voided urine samples from patients - \$400K (University requirements).

Year 1 + 2 - Company formation, patent registration, management and advertising - \$500K.

Milestones

1. The venture was recently accepted into the Ministry of Economy's accelerator program - MaofTech.
2. Funding and development plans were submitted to the venture by Albert Einstein College of Medicine in NY.

Tel: +97250-627-0399

Email: risin75@gmail.com

<https://www.linkedin.com/in/david-risin-b067b6122/?msgConversationId=6665323217403604992&msgOverlay=true>